Filing Details
- Accession Number:
- 0001140361-14-034864
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-09-04 17:54:07
- Reporting Period:
- 2014-09-02
- Filing Date:
- 2014-09-04
- Accepted Time:
- 2014-09-04 17:54:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
810509 | Navidea Biopharmaceuticals Inc. | NAVB | In Vitro & In Vivo Diagnostic Substances (2835) | 311080091 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1120642 | Uri Landesman | 30 00 47Th Ave Long Island City NY 11101 | No | No | Yes | No | |
1299265 | Platinum Partners Value Arbitrage Fund, Lp | C/O Walkers Corporate Services Limited Walker House, 87 Mary Street Georgetown, Grand Cayman E9 KY1-9002 | No | No | Yes | No | |
1339643 | Mark Nordlicht | 152 West 57Th Street 4Th Floor New York NY 10019 | No | No | Yes | No | |
1368616 | Platinum Management (Ny) Llc | 152 West 57Th Street 4Th Floor New York NY 10019 | No | No | Yes | No | |
1404598 | Platinum-Montaur Life Sciences, Llc | 152 West 57Th Street 4Th Floor New York NY 10019 | No | No | Yes | No | |
1476165 | L.p. Fund Master Opportunity Liquid Partners Platinum | 152 West 57 Street, 4Th Floor New York NY 10019 | No | No | Yes | No | |
1582140 | Platinum Liquid Opportunity Management (Ny) Llc | 152 West 57Th Street 4Th Floor New York NY 10019 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 | Disposition | 2014-09-02 | 60,000 | $1.36 | 14,946,431 | No | 4 | S | Indirect | By Platinum Partners Value Arbitrage Fund L.P. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By Platinum Partners Value Arbitrage Fund L.P. |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, Par Value $0.001 | 100,000 | Indirect | By Platinum Partners Liquid Opportunity Master Fund L.P. |
Footnotes
- This Form 4 is filed jointly by Platinum Partners Value Arbitrage Fund L.P. ("PPVA"), Platinum Partners Liquid Opportunity Master Fund L.P. ("PPLO"), Platinum-Montaur Life Sciences, LLC ("Platinum-Montaur"), Platinum Management (NY) LLC ("Platinum Management"), Platinum Liquid Opportunity Management (NY) LLC ("Platinum Liquid Management"), Mark Nordlicht and Uri Landesman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
- Securities owned directly by PPVA. Each of Platinum Management, as the Investment Manager of PPVA, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Management, may be deemed to beneficially own the securities owned directly by PPVA.
- Securities owned directly by PPLO. Each of Platinum Liquid Management, as the Investment Manager of PPLO, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Liquid Management, may be deemed to beneficially own the securities owned directly by PPLO.